GNI to Acquire Ayumi Pharmaceutical in 44.8 Billion Yen Deal; Blackstone-Backed Fund Becomes Top Shareholder

MT Newswires Live06-08 08:04

GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market, according to three Tokyo bourse filings on Friday.

To fund the acquisition, GNI will issue nearly 10 million new shares via third-party allotment to Ayumi's existing shareholders, namely Blackstone affiliate BCP Asia AYM, Toho (TYO:8129), and Hisamitsu Pharmaceutical (TYO:4530), with 26.8 billion yen of the purchase price settled through contribution in kind.

The remaining 18 billion yen will be paid in cash, partially financed through a 20 billion yen loan from Mizuho Bank and SBI Shinsei Bank.

As a result, BCP Asia AYM will become GNI's largest major shareholder with a 10.63% voting rights stake after the transaction.

The deal is expected to close between June and September, pending regulatory approvals and securities registration effectiveness.

Ayumi Pharmaceutical owns Ayumi Pharmaceutical Co., a maker of antipyretic analgesics and anti-rheumatic drugs, which has shown steady revenue growth from 31 billion yen to 38.5 billion yen over three years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641817438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641817438","market":"nz","top_or_hot":-1,"title":"GNI to Acquire Ayumi Pharmaceutical in 44.8 Billion Yen Deal; Blackstone-Backed Fund Becomes Top Shareholder","media":"MT Newswires Live","content":"<html><body><p> GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market, according to three Tokyo bourse filings on Friday.</p><p>To fund the acquisition, GNI will issue nearly 10 million new shares via third-party allotment to Ayumi's existing shareholders, namely <a href=\"https://laohu8.com/S/BX\">Blackstone</a> affiliate BCP Asia AYM, Toho (TYO:8129), and Hisamitsu Pharmaceutical (TYO:4530), with 26.8 billion yen of the purchase price settled through contribution in kind.</p><p>The remaining 18 billion yen will be paid in cash, partially financed through a 20 billion yen loan from Mizuho Bank and SBI Shinsei Bank.</p><p>As a result, BCP Asia AYM will become GNI's largest major shareholder with a 10.63% voting rights stake after the transaction.</p><p>The deal is expected to close between June and September, pending regulatory approvals and securities registration effectiveness.</p><p>Ayumi Pharmaceutical owns Ayumi Pharmaceutical Co., a maker of antipyretic analgesics and anti-rheumatic drugs, which has shown steady revenue growth from 31 billion yen to 38.5 billion yen over three years.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GNI to Acquire Ayumi Pharmaceutical in 44.8 Billion Yen Deal; Blackstone-Backed Fund Becomes Top Shareholder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGNI to Acquire Ayumi Pharmaceutical in 44.8 Billion Yen Deal; Blackstone-Backed Fund Becomes Top Shareholder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market, according to three Tokyo bourse filings on Friday.</p><p>To fund the acquisition, GNI will issue nearly 10 million new shares via third-party allotment to Ayumi's existing shareholders, namely <a href=\"https://laohu8.com/S/BX\">Blackstone</a> affiliate BCP Asia AYM, Toho (TYO:8129), and Hisamitsu Pharmaceutical (TYO:4530), with 26.8 billion yen of the purchase price settled through contribution in kind.</p><p>The remaining 18 billion yen will be paid in cash, partially financed through a 20 billion yen loan from Mizuho Bank and SBI Shinsei Bank.</p><p>As a result, BCP Asia AYM will become GNI's largest major shareholder with a 10.63% voting rights stake after the transaction.</p><p>The deal is expected to close between June and September, pending regulatory approvals and securities registration effectiveness.</p><p>Ayumi Pharmaceutical owns Ayumi Pharmaceutical Co., a maker of antipyretic analgesics and anti-rheumatic drugs, which has shown steady revenue growth from 31 billion yen to 38.5 billion yen over three years.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HEWJ","symbol_name":"日本ETF汇率对冲-iShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641817438","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641817438","pubTimestamp":1780877045,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HEWJ":"日本ETF汇率对冲-iShares","YCL":"ProShares Ultra Yen","YCS":"日元ETF-ProShares两倍做空","FXY":"日元ETF-CurrencyShares"},"translate_title":"GNI将以448亿日元收购步美制药；黑石支持的基金成为最大股东","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YCS":0.9,"HEWJ":0.9,"YCL":0.9,"FXY":0.9},"content_text":"GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market, according to three Tokyo bourse filings on Friday.To fund the acquisition, GNI will issue nearly 10 million new shares via third-party allotment to Ayumi's existing shareholders, namely Blackstone affiliate BCP Asia AYM, Toho (TYO:8129), and Hisamitsu Pharmaceutical (TYO:4530), with 26.8 billion yen of the purchase price settled through contribution in kind.The remaining 18 billion yen will be paid in cash, partially financed through a 20 billion yen loan from Mizuho Bank and SBI Shinsei Bank.As a result, BCP Asia AYM will become GNI's largest major shareholder with a 10.63% voting rights stake after the transaction.The deal is expected to close between June and September, pending regulatory approvals and securities registration effectiveness.Ayumi Pharmaceutical owns Ayumi Pharmaceutical Co., a maker of antipyretic analgesics and anti-rheumatic drugs, which has shown steady revenue growth from 31 billion yen to 38.5 billion yen over three years.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641817438","isCrawlerRequest":true}